Abstract
Topical cyclosporin A at a 2% concentration was used for 6 months in the management of 2 patients with vernal keratoconjunctivitis who had failed to respond to conventional therapy. We used one drop every 6 hours in both eyes during the first month and every 12 hours during the remaining 5 months. Clinical controls were carried out weekly during the first month, monthly during the 6 month period and every 2 months thereafter. Cyclosporin A blood levels and serum creatinine were regularly monitored in both patients. Within the first month, both the symptoms and signs of the condition, in particular papillary proliferations, improved significantly and these results were maintained throughout the entire period of treatment and during 2 years of follow-up with conservative management (artificial tears).
Similar content being viewed by others
Article PDF
References
BenEzra D, Pe'er J, Brodsky M, Cohen E . Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol 1986;101:278.
BenEzra D, Matamoros N, Cohen E . Treatment of severe vernal karatoconjunctivitis with cyclosporine A eyedrops. Transplant Proc 1988;22(2)(Suppl 2):644–9.
Secchi A, Tognon S, Leonardi A . Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990;110:641–5.
Bleik J, Tabbara K . Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991;98:1679–84.
Holland E, Olsen T, Ketcham J, Florine C, Krachmer J, Purcell J, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993;12:413–9.
Kaan G, Özden Ö . Therapeutic use of topical cyclosporine. Ann Ophthalmol 1993;25:182–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mendicute, J., Aranzasti, C., Eder, F. et al. Topical cyclosporin a 20% in the treatment of vernal keratoconjunctivitis. Eye 11, 75–78 (1997). https://doi.org/10.1038/eye.1997.14
Issue Date:
DOI: https://doi.org/10.1038/eye.1997.14